Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Eligible age
18+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 1 study to evaluate the safety and immunogenicity of Innocell, an autologous cellular immunotherapy made from patient-derived tumor cells, in female patients with recurrent epithelial ovarian cancer. Innocell autologous cellular immunotherapy consists of autologous tumor cells which have been inactivated using a proprietary light technology that inhibits cell replication while allowing for the cell to maintain antigen expression. These replication incompetent cells are then administered concurrently with an immunoadjuvant to stimulate a person's innate or adaptive immune response to vaccine antigens. This novel inactivation mechanism creates improved antigen presentation, specifically with presentation of the broad array of neoantigens unique to each patient's tumor.
Sponsor: PhotonPharma, Inc.
You may qualify if…
- ✓ 1. Age ≥ 18 years and female;
- ✓ 2. Has histologically or cytologically confirmed diagnosis of recurrent epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy and for whom single-agent therapy is appropriate as the next line of treatment;
- ✓ 3. Been treated with available standard-of-care therapy likely to convey clinical benefit (i.e., PARP inhibitors for women with germline BRCA mutation and in homologous recombination repair deficiency based on prior molecular testing or bevacizumab as appropriate);
- ✓ 4. Documented relapse or progression on or after the most recent line of therapy;
- ✓ 5. Patients must have at least 2 sites of measurable or detectable disease. The team will target to collect 1.0 gram of tumor tissue that can be removed and be available for manufacturing;
- ✓ 6. Eastern Collaborative Oncology Group (ECOG) performance status (PS) 0-2;
- ✓ 7. Recovery from clinically relevant toxicities to Grade 2 or less (except alopecia, peripheral neuropathy, and ototoxicity);
- ✓ 8. Adequate hematological, hepatic, and renal function obtained ≤ 28 days prior to planned initiation of vaccine series
You may not qualify if…
- ✕ 1. Patient known to be positive for HIV or patient with active HCV, HBV, HTLV-1/2;
- ✕ 2. Diagnosis of immunodeficiency, either primary or acquired;
- ✕ 3. Active autoimmune disease that required systemic disease modifying or immunosuppressive treatment within the last 12 months. Replacement therapy (e.g., thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is permitted;
- ✕ Note: The following conditions are permitted (i.e., not exclusionary) if the condition does not require immunosuppressive treatment:
- ✕ Type 1 diabetes (if stable, well controlled, and not brittle); Vitiligo; Hypo- or hyperthyroid disease; or Autoimmune alopecia.
- ✕ 4. Treatment with systemic steroids or any other form of immunosuppressive therapy within 14 days prior to planned initiation of the Innocell vaccine; Note: Inhaled or topical steroids, including mouthwash, and adrenal replacement doses are permitted in the absence of active autoimmune disease.
- ✕ 5. Congestive heart failure (NYHA Class II, III, or IV), unstable angina, ventricular or hemodynamically significant atrial arrhythmia, or cardiovascular disease such as stroke or myocardial infarction (current or within the past 6 months).
- ✕ 6. Has any acute infection that requires specific therapy. Acute therapy must be completed at least 7 days prior to initiation of Innocell series;
Where it's recruiting
Duarte
Source: ClinicalTrials.gov · NCT06366490 · last updated 2026-11-20